- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01904994
Link4Health: A Combination Strategy for Linkage and Retention, Swaziland (L4H)
LINK4HEALTH: A Combination Approach to Linkage and Retention for HIV (Human Immunodeficiency Virus) Infected Individuals in Swaziland
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Swaziland, Swaziland
- Bhalekane Clinic
-
Swaziland, Swaziland
- Dvokolwako
-
Swaziland, Swaziland
- Good Shepherd Hospital
-
Swaziland, Swaziland
- Hlatikhulu Hospital
-
Swaziland, Swaziland
- Horo
-
Swaziland, Swaziland
- Kamfishane
-
Swaziland, Swaziland
- Lamvelase
-
Swaziland, Swaziland
- Luyengo Clinic
-
Swaziland, Swaziland
- Mangweni Clinic
-
Swaziland, Swaziland
- Mankayane Hospital
-
Swaziland, Swaziland
- Mashobneni Clinic
-
Swaziland, Swaziland
- Mbabane Government Hospital
-
Swaziland, Swaziland
- Mkhuzweni Health Center
-
Swaziland, Swaziland
- Motshane
-
Swaziland, Swaziland
- Mpolenjeni Clinic
-
Swaziland, Swaziland
- Nhlangano Health Center
-
Swaziland, Swaziland
- Piggs Peak
-
Swaziland, Swaziland
- Raleigh Fitkin Memorial Hospital
-
Swaziland, Swaziland
- Siphofaneni Clinc
-
Swaziland, Swaziland
- Sithobeloa Rural Health Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥18 years
- Testing HIV-positive at an HTC (HIV testing and counseling) site within a SU (study unit)
- Willing to be referred to an HIV care clinic associated with the SU
- Willing to provide locator information
- Willing to adhere to study procedures, including a baseline interview, home-based interviews at 1 and 12 months after study enrollment; home-based CD4+ count assessment 12 months after enrollment, and abstraction of data from their medical records.
- Able to provide informed consent
Exclusion Criteria:
- Planning on leaving the community where they currently reside in the next 12 months for a period greater than 6 months
- Enrolled in HIV (Human immunodeficiency virus) care in the past 6 months at any HIV care clinic
- Currently on ART (antiretroviral therapy)
- Initiated ART (for any duration) in the past 6 months at any HIV care clinic
- Does not speak or understand English or si-Swati
- Reports being currently pregnant at time of study enrollment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Standard of Care
Participants will be managed per standard of care following prevailing Swaziland Ministry of Health guidelines.
|
|
|
Experimental: Combined Intervention Strategy
Point-of-care (POC) CD4+ (cluster of differentiation 4) Count Accelerated ART initiation for ART eligible participants Basic care and prevention package Cellular Appointment Reminders and Follow-Up Financial Incentives
|
Each HIV testing and counseling (HTC) site will be equipped with POC CD4+ testing using PIMA™ Analyser (Inverness), test strips, and reagents.
Study staff will obtain 25 microliters of blood via finger prick and process the POC (point-of-care) CD4+ (cluster of differentiation 4) Count' test immediately following the baseline interview.
Test results will be recorded on study forms including a referral form that has multiple copies, one copy to be given to the participant, the second sent to the affiliated HIV (Human immunodeficiency virus)care clinic in the study unit, and the third kept by study staff in a locked cabinet with other confidential material.
All participants, regardless of the CD4+ result, will be encouraged to enroll in HIV care as soon as they can.
Other Names:
Accelerated ART initiation for patients with POC CD4+ < 350 cells/uL (micro-liter) within 1 week from testing. 2 counseling sessions (one at time of HTC and other at first HIV clinic visit), and collection of blood for other baseline lab tests, but initiation prior to return of results for patients who do not meet criteria for waiting
Basic care and prevention package (BCPP) provided approximately every three months that includes: condoms; soap, pill box and pictorial education about use of materials and HIV, such as family testing tools and information.
Information on BCPP contents and review the educational materials will be provided.
An example of educational materials is a family-testing tool to encourage the participant to have all family members tested for HIV.
All BCPP items will be replenished every 3 months for all participants, regardless of ART status, beginning at linkage to HIV care.
Other Names:
SMS (short messaging service) appointment reminders for follow-up appointments. Telephone call within 7 days of missed appointment for all patients.
Participants will receive a series of financial incentives to support linkage into care within 1 month and retention in care at 6 months and 12 months after testing HIV positive.
The value of the financial incentive (FI) will be 80 Swaziland Rand, calculated based on the associated financial costs of traveling to clinic.
These incentives will be distributed by through mobile airtime.
Participants without mobile phones will be given an alternative incentive of equal value, such as a store voucher.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in proportion of participants who both link to care at assigned study unit within 1 month and are retained in care at the designated study unit 12 months after HIV (Human Immunodeficiency Virus) diagnosis
Time Frame: one month after enrollment, 12 months after enrollment
|
Combined outcome of linkage to HIV care within 1 month after testing HIV positive and retention in care 12 months after testing. Participants are considered to achieve this outcome if they successfully link to the HIV clinic at their study unit (SU) within 1 month of testing HIV positive and are retained in care at the HIV clinic at their SU 12 months after testing HIV positive, as measured from medical records. |
one month after enrollment, 12 months after enrollment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of participants successfully linked to care at designated study unit within 1 month of HIV diagnosis
Time Frame: 12 months after enrollment
|
Linkage to care within 1 month of HIV testing (at any clinic within the assigned study unit).
|
12 months after enrollment
|
|
Proportion of participants retained in care at designated study unit 12 months after HIV diagnosis.
Time Frame: 12 months after enrollment
|
Retention in care 12 months after HIV testing, independent of linkage at 1 month (at any clinic within the assigned study unit).
|
12 months after enrollment
|
|
Change in proportion of participants successfully linked to care at any HIV care clinic within one month of HIV diagnosis
Time Frame: one month after enrollment, 12 months after enrollment
|
Proportion of participants successfully linked to care at any HIV care clinic within one month of HIV diagnosis
|
one month after enrollment, 12 months after enrollment
|
|
Median time from HIV testing to initial assessment of ART (antiretroviral) eligibility
Time Frame: 12-months after enrollment
|
Time from linkage to ART eligibility assessment
|
12-months after enrollment
|
|
Median time from HIV testing to ART eligibility
Time Frame: 12 months after enrollment
|
Time from HIV testing to ART eligibility
|
12 months after enrollment
|
|
Proportion of participants who consistently engage in care (attend > 75% of scheduled appointments)
Time Frame: 12-months after enrollment
|
Proportion of participants who consistently engage in care, defined as attend > 75% of scheduled appointments
|
12-months after enrollment
|
|
Change in proportion of participants with new World Health Organization (WHO) Stage III/IV event or hospitalization
Time Frame: 1 month after enrollment,12 months after enrollment
|
Proportion of participants with new WHO Stage III/IV event or hospitalization
|
1 month after enrollment,12 months after enrollment
|
|
Median CD4+ (cluster difference 4) count and viral load 12 months after HIV diagnosis
Time Frame: 12 months after testing HIV-positive
|
Median CD4+ cell count 12 months after HIV diagnosis, median viral load 12 months after HIV diagnosis
|
12 months after testing HIV-positive
|
|
Change in Mortality rate
Time Frame: 1 month after enrollment, 12 months after enrollment
|
Mortality rate 12 months after HIV diagnosis
|
1 month after enrollment, 12 months after enrollment
|
|
Change in proportion of participants reporting interventions were received
Time Frame: 1 month after enrollment, 12 months after enrollment
|
Proportion of participants, who are randomized to study units receiving CIS, reporting receipt of each intervention
|
1 month after enrollment, 12 months after enrollment
|
|
Proportion of participants reporting that interventions were highly acceptable
Time Frame: 12 months after enrollment
|
Proportion of participants, who are randomized to study units receiving CIS, reporting that interventions were highly acceptable
|
12 months after enrollment
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in adjusted risk ratio comparing proportion of participants who both link to care at assigned study unit within one month and are retained in care at designated study unit twelve months after HIV diagnosis
Time Frame: at enrollment, one month after enrollment, 12 months after enrollment
|
Adjusted risk ratio comparing proportion of participants who both link to care at assigned study unit within one month and are retained in care at designated study unit twelve months after HIV diagnosis, by strata of age, sex, and other socio-demographic variables
|
at enrollment, one month after enrollment, 12 months after enrollment
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Wafaa El-Sadr, MD MPH, ICAP Columbia University
- Study Director: Charles Azih, MD MPH, Swaziland MOH
- Study Director: Scott Braithwaite, MD MSc, New York University
- Study Director: Batya Elul, PhD MD, ICAP Columbia University
- Study Director: Peter Ehrenkranz, MD MPH, Centers for Disease Control and Prevention
- Study Director: Matthew Lamb, PhD MPH, ICAP Columbia University
- Study Director: Margaret McNairy, MD MSc, ICAP Columbia University
- Study Director: Phumzile Mndzebele, Swaziland MOH
- Study Director: Ruben Sahabao, MD, ICAP Swaziland
Publications and helpful links
General Publications
- McNairy ML, Lamb MR, Gachuhi AB, Nuwagaba-Biribonwoha H, Burke S, Mazibuko S, Okello V, Ehrenkranz P, Sahabo R, El-Sadr WM. Effectiveness of a combination strategy for linkage and retention in adult HIV care in Swaziland: The Link4Health cluster randomized trial. PLoS Med. 2017 Nov 7;14(11):e1002420. doi: 10.1371/journal.pmed.1002420. eCollection 2017 Nov.
- McNairy ML, Gachuhi AB, Lamb MR, Nuwagaba-Biribonwoha H, Burke S, Ehrenkranz P, Mazibuko S, Sahabo R, Philip NM, Okello V, El-Sadr WM. The Link4Health study to evaluate the effectiveness of a combination intervention strategy for linkage to and retention in HIV care in Swaziland: protocol for a cluster randomized trial. Implement Sci. 2015 Jul 19;10:101. doi: 10.1186/s13012-015-0291-4.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immune System Diseases
- Slow Virus Diseases
- HIV Infections
- Acquired Immunodeficiency Syndrome
- Immunologic Deficiency Syndromes
- Anti-Infective Agents
- Antiviral Agents
- Anti-Retroviral Agents
Other Study ID Numbers
- AAAL2708
- 5R01AI100059-02 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV (Human Immunodeficiency Virus)
-
Merck Sharp & Dohme LLCWithdrawnHIV-1 | Immunodeficiency Virus Type 1, Human | Human Immunodeficiency Virus Type 1 | Human Immunodeficiency Virus 1
-
Indiana UniversityNational Institute on Aging (NIA)Enrolling by invitationHIV | Geriatric | Geriatric Assessment | HIV - Human Immunodeficiency Virus | HIV (Human Immunodeficiency Virus)United States
-
National Institute of Allergy and Infectious Diseases...CompletedHuman Immunodeficiency Virus (HIV) | Human Immunodeficiency Virus PreventionUnited States
-
RTI InternationalCenters for Disease Control and PreventionCompletedHuman Immunodeficiency Virus (HIV) PositiveUnited States
-
Bristol-Myers SquibbCompleted
-
Janssen-Cilag International NVCompletedHuman Immunodeficiency Virus (HIV) Infections | Acquired Immunodeficiency Syndrome (AIDS) VirusFrance, United Kingdom, Belgium, Germany, Spain, Switzerland, Denmark, Israel, Austria, Poland, Hungary, Sweden, Ireland
-
Merck Sharp & Dohme LLCRecruitingHuman Immunodeficiency Virus (HIV) InfectionUnited States, South Africa, Thailand, Colombia, Mexico, Russia
-
Janssen Inc.CompletedHuman Immunodeficiency Virus (HIV)Canada
-
Columbia UniversityMinistry of Health, SwazilandCompleted
-
Bristol-Myers SquibbMedarexCompletedHuman Immunodeficiency Virus (HIV)United States
Clinical Trials on POC (point-of-care) CD4+ (cluster of differentiation 4) Count
-
Assistance Publique - Hôpitaux de ParisCompleted
-
University of Maryland, BaltimoreDexCom, Inc.CompletedDiabetes MellitusUnited States
-
Sherief Abd-ElsalamRecruitingEndotracheal Tube Wrongly Placed During Anesthetic ProcedureEgypt
-
Elizabeth Glaser Pediatric AIDS FoundationUNITAIDCompletedHIV Infections | HIV/AIDS | Infant Morbidity | Perinatal HIV InfectionZimbabwe
-
The Aurum Institute NPCLondon School of Hygiene and Tropical Medicine; Johns Hopkins University; United... and other collaboratorsCompleted
-
Loma Linda UniversityCompletedEndotracheal Tube Wrongly Placed During Anesthetic ProcedureUnited States
-
The University of Texas Health Science Center,...TerminatedAmniotic Fluid; Disorder | Fetal Growth AbnormalityUnited States
-
Soroka University Medical CenterCompletedThyroglobulin Point of Care Assay for Rapid Detection of Metastatic Differentiated Thyroid CarcinomaDifferentiated Thyroid Cancer | Lymph Node MetastasesIsrael
-
Michael HoelscherClinton Health Access Initiative Inc.; Instituto Nacional de Saúde (INS), Ministério... and other collaboratorsCompletedHIV, Neonatal HIV Early-Infant-Diagnosis (EID), Point-of-Care Testing (PoC)Mozambique, Tanzania
-
Elizabeth Glaser Pediatric AIDS FoundationUNITAIDCompletedHIV/AIDS | Infant Morbidity | Pediatric HIV Infection | Transmission, Perinatal InfectionKenya, Zimbabwe